2型糖尿病无心血管或肾脏疾病患者长期使用SGLT2i与DPP4i的肾脏结局真实世界研究
基于以色列大型数据库的倾向评分匹配队列研究,纳入19648例2型糖尿病患者,比较SGLT2i与DPP4i的长期肾脏结局。在中位随访38个月中,SGLT2i与较低的肾脏特异性复合结局和肾脏或死亡结局风险相关,且在无心血管或肾脏疾病证据的亚组中,SGLT2i仍与减缓eGFR下降相关。
要点
- SGLT2i与DPP4i相比,肾脏特异性复合结局风险较低(HR 0.72)。
- 在无心血管或肾脏疾病证据的患者中,SGLT2i与减缓eGFR下降相关。
- SGLT2i与DPP4i相比,肾脏或死亡结局风险较低(HR 0.80)。
核心结论
- 在真实世界环境中,长期使用SGLT2i与DPP4i相比,与2型糖尿病患者eGFR下降减缓相关,即使在基线时无心血管或肾脏疾病证据的患者中也是如此。
研究设计与样本
- 基于以色列大型数据库的倾向评分匹配(1:1)队列研究,纳入2015年至2021年间开始使用SGLT2i或DPP4i的2型糖尿病患者,共匹配19648例,其中10467例(53%)无心血管或肾脏疾病证据。
主要发现
- 肾脏特异性复合结局(确认eGFR下降≥40%或肾衰竭)在SGLT2i组与DPP4i组的事件率分别为6.9例/1000患者年与9.5例/1000患者年。
- 肾脏或死亡结局的事件率在SGLT2i组与DPP4i组分别为17.7例/1000患者年与22.1例/1000患者年。
- 与DPP4i相比,SGLT2i与较低的肾脏特异性结局风险相关(HR 0.72;95%CI 0.61-0.86;P<0.001)和较低的肾脏或死亡结局风险相关(HR 0.80;95%CI 0.71-0.89;P<0.001)。
- 在无心血管或肾脏疾病证据的患者中,肾脏特异性结局的HR为0.67(95%CI 0.44-1.02),肾脏或死亡结局的HR为0.77(95%CI 0.61-0.97)。
- SGLT2i与DPP4i相比,与eGFR斜率减缓相关,总体组间平均差异为0.49(95%CI 0.35-0.62)ml/min per 1.73 m² per year,在无心血管或肾脏疾病证据的患者中为0.48(95%CI 0.32-0.64)ml/min per 1.73 m² per year。
关键数值与推荐
- 肾脏特异性复合结局定义为确认的eGFR下降≥40%或肾衰竭。
- 肾脏或死亡结局包括全因死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Contemporary guidelines recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) independently of glycemic control in patients with type 2 diabetes and those with kidney disease, with heart failure, or at high risk of cardiovascular disease. Using a large Israeli database, we assessed whether long-term use of SGLT2is versus dipeptidyl peptidase 4 inhibitors (DPP4is) is associated with kidney benefits in patients with type 2 diabetes overall and in those without evidence of cardiovascular or kidney disease. METHODS: Patients with type 2 diabetes who initiated SGLT2is or DPP4is between 2015 and 2021 were propensity score-matched (1:1) according to 90 parameters. The kidney-specific composite outcome included confirmed ≥40% decline in eGFR or kidney failure. The kidney-or-death outcome included also all-cause mortality. Risks of outcomes were assessed using Cox proportional hazard regression models. The between-group difference in eGFR slope was also assessed. Analyses were repeated in patients' subgroup lacking evidence of cardiovascular or kidney disease. RESULTS: Overall, 19,648 propensity score-matched patients were included; 10,467 (53%) did not have evidence of cardiovascular or kidney disease. Median follow-up was 38 months (interquartile range, 22-55). The composite kidney-specific outcome occurred at an event rate of 6.9 versus 9.5 events per 1000 patient-years with SGLT2i versus DPP4i. The respective event rates of the kidney-or-death outcome were 17.7 versus 22.1. Compared with DPP4is, initiation of SGLT2is was associated with a lower risk for the kidney-specific (hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.61 to 0.86; P < 0.001) and kidney-or-death (HR, 0.80; 95% CI, 0.71 to 0.89; P < 0.001) outcomes. The respective HRs (95% CI) in those lacking evidence of cardiovascular or kidney disease were 0.67 (0.44 to 1.02) and 0.77 (0.61 to 0.97). Initiation of SGLT2is versus DPP4is was associated with mitigation of the eGFR slope overall and in those lacking evidence of cardiovascular or kidney disease (mean between-group differences 0.49 [95% CI, 0.35 to 0.62] and 0.48 [95% CI, 0.32 to 0.64] ml/min per 1.73 m 2 per year, respectively). CONCLUSIONS: Long-term use of SGLT2is versus DPP4is in a real-world setting was associated with mitigation of eGFR loss in patients with type 2 diabetes, even in those lacking evidence of cardiovascular or kidney disease at baseline.
引用
- Melzer Cohen C, Schechter M, Rozenberg A, et al. Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease. Clin J Am Soc Nephrol. 2023. PMID: 37382938. doi:10.2215/CJN.0000000000000218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。